Literature DB >> 30310959

Prevalence, risk factors and therapeutic aspects of injuries and accidents in women with epilepsy.

René Danilo Verboket1, Nicolas Söhling2, Ingo Marzi2, Esther Paule3, Susanne Knake4, Felix Rosenow3,4, Adam Strzelczyk3,4, Laurent Maximilian Willems3.   

Abstract

BACKGROUND: Epilepsy-related injuries and accidents (ERIA) are a frequent cause of hospitalisation and represent a relevant burden for patients with epilepsy. In particular, osteoporosis and other gender-specific aspects may increase the risk of seizure-related fractures and injuries in women with epilepsy. AIM AND SCOPE: The aim of this analysis is to determine the prevalence and clinical nature of ERIA in a cohort of women with epilepsy, to identify possible determinants including osteoporosis and to give an overview of the current knowledge of clinically important prophylactic and therapeutic aspects.
RESULTS: In total, 167 women (mean age 39.0 years, range 18-67 years) with established diagnosis of epilepsy (mean disease duration 18.2 years, range 0-64) were analysed for the occurrence of ERIA. Overall, 22 patients (13.2%) reported at least one ERIA (mean number 3.4, ± 3.1) during the last three months prior to enrollment. The most frequent types of ERIA were lacerations (n = 7/22; 31.8%), abrasions, cuts, bruises or hematoma (n = 6/22, 27.3%), burns (n = 3/22, 13.6%), and fractures (n = 3/22, 13.6%). Moreover, one seizure-related road traffic accident with consecutive trauma (4.5%) was reported. Ictal falls, periictal abnormalities of behaviour and missing seizure freedom were associated with ERIA. Furthermore, female patients with ERIA had a significantly reduced quality of life (QoL, p = 0.002) and increased anxiety (p = 0.008) compared to patients without ERIA. A review of the pertinent literature suggests decreased bone mineral density and use of enzyme-inducing AEDs to be risk factors for ERIA in women with epilepsy.
CONCLUSION: ERIA represent relevant complications for women with epilepsy and are associated with a lower QoL and anxiety compared with non-affected controls. Improvement of anticonvulsive treatment and therapy for osteoporosis or osteomalacia may help to decrease ERIA and the associated burden.

Entities:  

Keywords:  Burden; Female; Fracture; Osteoporosis; Quality of life; Seizure

Mesh:

Year:  2018        PMID: 30310959     DOI: 10.1007/s00068-018-1030-8

Source DB:  PubMed          Journal:  Eur J Trauma Emerg Surg        ISSN: 1863-9933            Impact factor:   3.693


  5 in total

1.  Automatic Detection of Epilepsy Based on Entropy Feature Fusion and Convolutional Neural Network.

Authors:  Yongxin Sun; Xiaojuan Chen
Journal:  Oxid Med Cell Longev       Date:  2022-05-11       Impact factor: 7.310

2.  Seizure related injuries - Frequent injury patterns, hospitalization and therapeutic aspects.

Authors:  Nils Mühlenfeld; Philipp Störmann; Ingo Marzi; Felix Rosenow; Adam Strzelczyk; René D Verboket; Laurent M Willems
Journal:  Chin J Traumatol       Date:  2021-10-15

3.  Risk incidence of fractures and injuries: a multicenter video-EEG study of 626 generalized convulsive seizures.

Authors:  Katharina Frey; Johann Philipp Zöllner; Susanne Knake; Yulia Oganian; Lara Kay; Katharina Mahr; Fee Keil; Laurent M Willems; Katja Menzler; Sebastian Bauer; Susanne Schubert-Bast; Felix Rosenow; Adam Strzelczyk
Journal:  J Neurol       Date:  2020-07-10       Impact factor: 4.849

4.  [Cost factor "outpatient wound care" in the emergency department : Cost-revenue deficit of outpatient wound treatment in a German university hospital].

Authors:  Cora R Schindler; Thomas Lustenberger; Ingo Marzi; René D Verboket
Journal:  Unfallchirurg       Date:  2021-01       Impact factor: 1.000

5.  [Inpatient treatment costs, cost-driving factors and potential reimbursement problems due to epileptic seizure-related injuries and fractures].

Authors:  René D Verboket; Nils Mühlenfeld; Jasmina Sterz; Philipp Störmann; Ingo Marzi; Yunus Balcik; Felix Rosenow; Adam Strzelczyk; Laurent M Willems
Journal:  Chirurg       Date:  2021-04       Impact factor: 0.955

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.